Criteria to qualify for study: | Drug used in study: |
---|---|
|
HR 61 A Phase 1 Study of SEA-CD70 as monotherapy or in combination, in AML or MDS |
|
BMT 30 Graft-versus-tumor augmentation with Nivolumab for high risk patients with MDS and AML after Allogeneic Stem Cell Transplantation using post transplantation Cyclophosphamide. |